# Procter & Gamble Hygiene and Health Care share price today (Procter & Gamble Hygiene and Health Care Ltd, NSE: PGHH)

> Procter & Gamble Hygiene and Health Care share price today: ₹7,056.50 at the NSE close on 3 November 2026, down 47.1% in a year. Procter & Gamble Hygiene and Health Care (NSE: PGHH) is worth ₹22,906 crore, trades at a P/E of 28.9 and has closed between ₹6,639.00 and ₹13,174.00 over the past 52 weeks. > Procter & Gamble Hygiene and Health Care Ltd's P/E is near the low end of its own history, higher than only 1% of past readings, and its quarterly results are still getting worse. PGHH · FMCG - Personal Care · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/procter-gamble-hygiene-and-health-care-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹7,056.50 (−47.1% in a year)
- P/E: 28.9× (lower than 99% of the last 11 years)
- Revenue (Jun 2026): ₹891 Cr (−4.9% on a year ago)
- Profit (Jun 2026): ₹126 Cr (−34.4% on a year ago)
- Operating margin: 19.0% (−9.0 points on a year ago)
- ROCE: 157%, Mar 2026
- ROIC: 398.8%, against a 12.0% cost of capital: +386.8 points

The main question: yearly earnings per share moved +34.5% while the share price moved −47.1%. ## What is the Procter & Gamble Hygiene and Health Care share price today? Procter & Gamble Hygiene and Health Care Ltd's share price was ₹7,056.50 at the close on 3 November 2026. It has been falling for 102 weeks. That is 23.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹6,639 and ₹13,174, and at that close it sat 6% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 57 weeks running. Over the last 11 years the share price moved +12% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 24 October 2025. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Procter & Gamble Hygiene and Health Care this quarter? Three changes stood out: lowest operating margin in 8 quarters, indian funds and insurers (DIIs) cut their stake for 4 quarters in a row and number of shareholders up 29% in a year. 1. Lowest operating margin in 8 quarters Operating margin was 19% in the June 2026 quarter, against 28% a year earlier. 2. Indian funds and insurers (DIIs) cut their stake for 4 quarters in a row From 16.1% to 15% of the company by the September 2026 quarter. 3. Number of shareholders up 29% in a year 64,415 shareholders in the September 2026 quarter, against 49,997 a year earlier. ## What dividend does Procter & Gamble Hygiene and Health Care pay? Procter & Gamble Hygiene and Health Care paid ₹230 a share in regular dividends in the 12 months to 4 November 2026 (2 payments), a yield of 3.26% at the ₹7,056.50 close on 3 November 2026. The last was a dividend of ₹60 a share, ex-date 1 September 2026. ### Procter & Gamble Hygiene and Health Care dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 1 Sep 2026 | ₹60 | Dividend | same day |
| 5 Feb 2026 | ₹195 | Interim + Special | same day |
| 28 Aug 2025 | ₹65 | Dividend | same day |
| 20 Feb 2025 | ₹110 | Interim | same day |
| 19 Nov 2024 | ₹95 | Dividend | n/a |
| 9 Feb 2024 | ₹160 | Interim + Special | same day |
| 17 Nov 2023 | ₹105 | Dividend | n/a |
| 8 Feb 2023 | ₹80 | Interim | same day |
| 4 Nov 2022 | ₹65 | Dividend | n/a |
| 8 Feb 2022 | ₹95 | Interim | 9 Feb 2022 |
| 9 Nov 2021 | ₹80 | Dividend | n/a |
| 11 May 2021 | ₹150 | Special | 12 May 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

₹25 Special dividends, last 12 months

Yes. Procter & Gamble Hygiene and Health Care Ltd paid out 97% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What are Procter & Gamble Hygiene and Health Care's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Procter & Gamble Hygiene and Health Care reported revenue of ₹891 crore, down 4.9% from ₹937 crore a year earlier, and a profit of ₹126 crore, down 34.4% from ₹192 crore. ### Procter & Gamble Hygiene and Health Care results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹891 crore | ₹937 crore | −4.9% |
| Profit | ₹126 crore | ₹192 crore | −34.4% |
| Earnings per share | ₹38.90 | ₹59.17 | −34.3% |
| Operating margin | 19.0% | 28.0% | −9.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Procter & Gamble Hygiene and Health Care share price history? Procter & Gamble Hygiene and Health Care closed at ₹7,056.50 on 3 November 2026, down 47.1% from ₹13,351.00 a year earlier (31 October 2025) and down 51.0% over five years. Its highest weekly close since March 2016 was ₹18,427.55 on 17 November 2023. ### Procter & Gamble Hygiene and Health Care share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹6,825.00 | +3.4% |
| 1 month ago · 1 Oct 2026 | ₹6,639.00 | +6.3% |
| 6 months ago · 30 Apr 2026 | ₹10,146.50 | −30.5% |
| 1 year ago · 31 Oct 2025 | ₹13,351.00 | −47.1% |
| 3 years ago · 3 Nov 2023 | ₹17,538.10 | −59.8% |
| 5 years ago · 4 Nov 2021 | ₹14,411.50 | −51.0% |
| 10 years ago · 4 Nov 2016 | ₹7,001.85 | +0.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹6,278.80 | +12.4% |
| Highest weekly close since March 2016 · 17 Nov 2023 | ₹18,427.55 | −61.7% |
| Lowest weekly close since March 2016 · 1 Apr 2016 | ₹6,206.10 | +13.7% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹13,174.00 | −46.4% |
| 52-week low (weekly close) · 1 Oct 2026 | ₹6,639.00 | +6.3% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (560 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Procter & Gamble Hygiene and Health Care? 3 Nov 2026: Procter & Gamble Hygiene and Health Care closed at ₹7,056.50, up 3.4% on the week and up 6.3% on the month. 1 Sep 2026: ex-date for a dividend of ₹60 a share. ### Earlier

- Results for April to June 2026: Revenue down 4.9% and profit down 34.4% on a year earlier. - 5 Feb 2026: ex-date for an interim + special dividend of ₹195 a share. ## Which stock lists is Procter & Gamble Hygiene and Health Care on? Procter & Gamble Hygiene and Health Care is on 3 of our India lists: 52 week high & low, Dividend stocks and Small & mid cap stocks. - [52 week high & low 52-week position: Near 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india)
- [Dividend stocks Regular dividend yield (%): 3.34](https://www.sectoralpha.in/dividend-stocks-india)
- [Small & mid cap stocks Size rank in India: 337](https://www.sectoralpha.in/small-cap-stocks-india)

## Is Procter & Gamble Hygiene and Health Care profitable? Procter & Gamble Hygiene and Health Care Ltd earned ₹126 Cr of net profit in the Jun 2026 quarter, −34.4% on the same quarter a year earlier. Full-year Mar 2026 profit was ₹856 Cr. Over 10 years profit has grown 7.3% a year on average. That is 14.1% of the quarter's revenue. The same quarter a year earlier earned ₹192 Cr. Why profit moved: revenue changed −4.9% on a year earlier and the margin moved −9.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −6.3% and revenue −1.9%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Procter & Gamble Hygiene and Health Care make, and is it growing? Procter & Gamble Hygiene and Health Care Ltd reported ₹891 Cr of revenue in the Jun 2026 quarter, −4.9% on the same quarter a year earlier. Over 10 years it has grown 6.5% a year on average. The last full year, Mar 2026, came in at ₹4,290 Cr. The last four reported quarters add to ₹4,244 Cr. Mar 2026 revenue was ₹4,290 Cr, +27.1% on the year before. Recent pace: the last four quarters grew −1.9% on average, against 6.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −1.6%, against +0.5% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −4.7%, against +8.2% a year (rolling over). ## How much of every ₹100 of sales does Procter & Gamble Hygiene and Health Care keep? Procter & Gamble Hygiene and Health Care Ltd's operating margin was 19.0% in the Jun 2026 quarter, 9.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 20.0% and 29.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −9.3 percentage points on the year while gross margin changed −6.2 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Procter & Gamble Hygiene and Health Care's profit turning into cash? Over the last 3 years, 92% of Procter & Gamble Hygiene and Health Care Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In Mar 2026 it brought in ₹924 Cr of operating cash against ₹856 Cr of profit. After ₹49.0 Cr of spending on assets, ₹875 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 92% of profit came in as cash: the cash cycle got 18 days longer between FY21 and Mar 2026, so more of each rupee of profit waits in the business before it arrives. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Procter & Gamble Hygiene and Health Care's cash go? Procter & Gamble Hygiene and Health Care Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −126 days in Mar 2026, up from −144 days in FY21. It spent ₹122 Cr on assets over the last 3 years. Customers take 21 days to pay, and stock sits for 51 days on average. At Mar 2026 sales of ₹4,290 Cr, each day of that cycle ties up about ₹11.8 Cr, so roughly −₹1,481 Cr is tied up in the business at any time. Mar 26: customers took 21 days to pay and stock sat for 51 days, about 1.7 months of sales sitting as stock, for a full cycle of −126 days, longer than FY21's −144. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 51 days. Customers pay about 21 days after that. Suppliers are paid at 197 days. Together that makes the −126-day cycle. Spending on assets: ₹122 Cr over the last 3 years, against ₹151 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹21.0 Cr (Mar 2026): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Procter & Gamble Hygiene and Health Care's P/E ratio, and how does it compare with its own history? Procter & Gamble Hygiene and Health Care Ltd's P/E is 28.9×, about the lowest it has ever been. Its usual P/E (the middle reading) is 72.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +34.5% while the price moved −47.1%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −13.3% a year; about +3.9% a year came from earnings growth and about −17.2 percentage points from the multiple (the market paying less); over 10 years the price moved +0.1% a year; about +5.6% a year came from earnings growth and about −5.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Procter & Gamble Hygiene and Health Care business getting better or worse? Procter & Gamble Hygiene and Health Care Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE rising at 125.6%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Procter & Gamble Hygiene and Health Care earn on its capital? Procter & Gamble Hygiene and Health Care Ltd earned a ROCE of 157% in Mar 2026. That is up from a low of 45% in FY16. Its return on capital used (ROIC) is 386.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 20.0% net margin and 2.38× asset turnover (sales divided by assets). Why the return is what it is (Mar 2026): a 20.0% net margin × 2.38× asset turnover × 2.40× leverage (assets divided by equity) ≈ 114.2% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 398.8% − 12.0% = +386.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 398.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 360.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Procter & Gamble Hygiene and Health Care have too much debt? Procter & Gamble Hygiene and Health Care Ltd has total debt of ₹1.0 Cr against shareholder equity of ₹753 Cr as of Jun 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.00 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Procter & Gamble Hygiene and Health Care shareholding pattern? No group of Procter & Gamble Hygiene and Health Care Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved −0.3 points over the same period, to 15.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −0.9 points over 8 quarters, to 0.6%; Domestic institutions: −0.3 points over 8 quarters, to 15.0%; Promoters: +0.0 points over 8 quarters, to 70.6%. ## How far is Procter & Gamble Hygiene and Health Care from balance-sheet trouble? For Procter & Gamble Hygiene and Health Care Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Procter & Gamble Hygiene and Health Care rank in its industry? 52.3 out of 100, rank 5 of 12 in FMCG - Personal Care, with 81% of the evidence available. Procter & Gamble Hygiene and Health Care Ltd scores 52.3 out of 100 against the 12 companies it is compared with in FMCG - Personal Care, ranking 5. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. The four parts add up to the total exactly: 13.9 + 17.6 + 13.3 + 7.5 = 52.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Procter & Gamble Hygiene and Health Care compared with? Procter & Gamble Hygiene and Health Care ranks 5 of 12 FMCG - Personal Care companies on the 4-Factor Sector Score, with 52.3 out of 100. 1. [Bajaj Consumer Care Ltd](https://www.sectoralpha.in/stocks/bajaj-consumer-care-ltd) BAJAJCON · quiet · Most evidence points up · 100% evidence 70.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.7/35 · Revenue 28% · Profit 84.6% · Operating margin change 7 points · 100% evidence Capital efficiency 19.2/25 · ROCE 30% · Operating margin 25% · 100% evidence Valuation 11.7/20 · P/E 19.3× · PEG 1.64 · 100% evidence Relative strength 6.5/20 · Lead over its industry 0.2% · Lead over NIFTY 500 -10.2% · 1 year 33.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 32.7 + 19.2 + 11.7 + 6.5 = 70.1 · What this means: Earnings are strong; relative strength in its sector is 0.2% and the one-year return is 33.5%. 2. [Hindustan Unilever Ltd](https://www.sectoralpha.in/stocks/hindustan-unilever-ltd) HINDUNILVR · basing · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.4/35 · Revenue 9.5% · Profit 38% · Operating margin change -2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 28.4% · Operating margin 22% · 100% evidence Valuation 17.2/20 · P/E 39.1× · PEG 0.72 · 100% evidence Relative strength 12.8/20 · Lead over its industry 1% · Lead over NIFTY 500 -9.9% · 1 year -21% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.4 + 15.8 + 17.2 + 12.8 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Marico Ltd](https://www.sectoralpha.in/stocks/marico-ltd) MARICO · quiet · Most evidence points up · 78% evidence 66.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 25.1% · Profit 15% · Operating margin change 1 points · 83% evidence Capital efficiency 17.9/25 · ROCE 47% · Operating margin 21% · 76% evidence Valuation 6.8/20 · P/E 55.1× · PEG n/a · 50% evidence Relative strength 17.4/20 · Lead over its industry 18.9% · Lead over NIFTY 500 6.5% · 1 year 11.2% · 100% evidence · 1 of 12 weeks ahead Exact sum: 24.4 + 17.9 + 6.8 + 17.4 = 66.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gillette India Ltd](https://www.sectoralpha.in/stocks/gillette-india-ltd) GILLETTE · turning · Evidence leans up · 81% evidence 64.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 8% · Profit 18.4% · Operating margin change -1 points · 88% evidence Capital efficiency 18.1/25 · ROCE 90.7% · Operating margin 29% · 100% evidence Valuation 13.6/20 · P/E 34.5× · PEG 1.7 · 100% evidence Relative strength 10.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -5.5% · 1 year -21.5% · 25% evidence · 0 of 12 weeks ahead Exact sum: 23 + 18.1 + 13.6 + 10.1 = 64.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. Procter & Gamble Hygiene and Health Care Ltd this page PGHH · basing · Evidence leans up · 81% evidence 52.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue -1.6% · Profit -4.7% · Operating margin change -9 points · 88% evidence Capital efficiency 17.6/25 · ROCE 157% · Operating margin 19% · 100% evidence Valuation 13.3/20 · P/E 28.1× · PEG 1.77 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -27.7% · 1 year -48.7% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.9 + 17.6 + 13.3 + 7.5 = 52.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 6. [Colgate-Palmolive (India) Ltd](https://www.sectoralpha.in/stocks/colgate-palmolive-indialtd) COLPAL · quiet · Evidence leans up · 85% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.5/35 · Revenue 8.7% · Profit 2.6% · Operating margin change -3 points · 100% evidence Capital efficiency 21.6/25 · ROCE 108% · Operating margin 28% · 100% evidence Valuation 8.4/20 · P/E 31.4× · PEG 6.07 · 100% evidence Relative strength 8.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.1% · 1 year -28.8% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12.5 + 21.6 + 8.4 + 8.5 = 51 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Dabur India Ltd](https://www.sectoralpha.in/stocks/dabur-india-ltd) DABUR · basing · Evidence leans up · 81% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.2/35 · Revenue 7.4% · Profit 10.9% · Operating margin change 0 points · 88% evidence Capital efficiency 14.9/25 · ROCE 20.3% · Operating margin 20% · 100% evidence Valuation 9.1/20 · P/E 32.7× · PEG 5.04 · 100% evidence Relative strength 8.8/20 · Lead over its industry n/a · Lead over NIFTY 500 -14.7% · 1 year -25% · 25% evidence · 0 of 12 weeks ahead Exact sum: 18.2 + 14.9 + 9.1 + 8.8 = 51 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Emami Ltd](https://www.sectoralpha.in/stocks/emami-ltd) EMAMILTD · basing · Evidence leans down · 96% evidence 43.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.0/35 · Revenue 2.8% · Profit -8.2% · Operating margin change -1 points · 88% evidence Capital efficiency 15.1/25 · ROCE 28.1% · Operating margin 22% · 100% evidence Valuation 8.9/20 · P/E 20.7× · PEG 2.99 · 100% evidence Relative strength 10.1/20 · Lead over its industry -3.2% · Lead over NIFTY 500 -13.6% · 1 year -32.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 9 + 15.1 + 8.9 + 10.1 = 43.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Zydus Wellness Ltd](https://www.sectoralpha.in/stocks/zydus-wellness-ltd) ZYDUSWELL · quiet · Evidence leans down · 96% evidence 39.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.8/35 · Revenue 66.3% · Profit -42.5% · Operating margin change -1 points · 88% evidence Capital efficiency 7.9/25 · ROCE 4.9% · Operating margin 17% · 100% evidence Valuation 6.0/20 · P/E 66.5× · PEG 1.75 · 100% evidence Relative strength 12.7/20 · Lead over its industry 12.9% · Lead over NIFTY 500 1.1% · 1 year -2.9% · 100% evidence · 2 of 12 weeks ahead Exact sum: 12.8 + 7.9 + 6 + 12.7 = 39.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Godrej Consumer Products Ltd](https://www.sectoralpha.in/stocks/godrej-consumer-products-ltd) GODREJCP · quiet · Evidence leans down · 100% evidence 35.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 12.9% · Profit 8.6% · Operating margin change -1 points · 100% evidence Capital efficiency 10.3/25 · ROCE 18.8% · Operating margin 19% · 100% evidence Valuation 4.3/20 · P/E 39.4× · PEG 7.49 · 100% evidence Relative strength 2.9/20 · Lead over its industry -8.6% · Lead over NIFTY 500 -18.5% · 1 year -26.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 18.1 + 10.3 + 4.3 + 2.9 = 35.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Jyothy Labs Ltd](https://www.sectoralpha.in/stocks/jyothy-labs-ltd) JYOTHYLAB · quiet · Most evidence points down · 96% evidence 34.0 out of 100 Growth Capital Valuation Relative
12. [Polo Queen Industrial and Fintech Ltd](https://www.sectoralpha.in/stocks/polo-queen-industrial-and-fintech-ltd) PQIF · Too little evidence to rank firmly · 33% evidence 39.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [FMCG - Personal Care](https://www.sectoralpha.in/sectors/fmcg-personal-care), all 12 compared on one page. ## Which companies are close to Procter & Gamble Hygiene and Health Care in size? Procter & Gamble Hygiene and Health Care is the 7th largest of 12 FMCG - Personal Care companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Dabur India, Colgate-Palmolive (India) and Gillette India. Just below it: Emami, Zydus Wellness and Jyothy Labs. ### FMCG - Personal Care companies close in size

1. [Dabur India Ltd](https://www.sectoralpha.in/stocks/dabur-india-ltd) ₹64,856 crore
2. [Colgate-Palmolive (India) Ltd](https://www.sectoralpha.in/stocks/colgate-palmolive-indialtd) ₹43,423 crore
3. [Gillette India Ltd](https://www.sectoralpha.in/stocks/gillette-india-ltd) ₹23,064 crore
4. Procter & Gamble Hygiene and Health Care Ltd ₹22,239 crore
5. [Emami Ltd](https://www.sectoralpha.in/stocks/emami-ltd) ₹15,703 crore
6. [Zydus Wellness Ltd](https://www.sectoralpha.in/stocks/zydus-wellness-ltd) ₹14,723 crore
7. [Jyothy Labs Ltd](https://www.sectoralpha.in/stocks/jyothy-labs-ltd) ₹6,313 crore

[All 12 FMCG - Personal Care companies, largest first](https://www.sectoralpha.in/sectors/fmcg-personal-care#all-companies)

### Companies close in size in other industries

1. [Prime Focus Ltd](https://www.sectoralpha.in/stocks/prime-focus-ltd) ₹22,436 crore · Entertainment & Media
2. [Garden Reach Shipbuilders & Engineers Ltd](https://www.sectoralpha.in/stocks/garden-reach-shipbuilders-engineers-ltd) ₹22,265 crore · Ship - Docks/Breaking/Repairs
3. Procter & Gamble Hygiene and Health Care Ltd ₹22,239 crore
4. [Hatsun Agro Product Ltd](https://www.sectoralpha.in/stocks/hatsun-agro-product-ltd) ₹22,175 crore · FMCG - Dairy Products
5. [HBL Engineering Ltd](https://www.sectoralpha.in/stocks/hbl-engineering-ltd) ₹22,158 crore · Railways - Kavach/Springs

## What else do people ask about Procter & Gamble Hygiene and Health Care? ### What is Procter & Gamble Hygiene and Health Care's share price today? Procter & Gamble Hygiene and Health Care Ltd's share price is ₹7,056.50, −47.1% over the past year. The whole company is worth ₹22,906 Cr on the market. The price has been falling for 102 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 57 weeks running (as of 3 November 2026). ### What were Procter & Gamble Hygiene and Health Care's latest quarterly results? Procter & Gamble Hygiene and Health Care Ltd reported revenue of ₹891 Cr and net profit of ₹126 Cr for the Jun 2026 quarter. Revenue fell 4.9% and profit fell 34.4% compared with a year earlier. Earnings per share were ₹38.90 (as of 3 November 2026). ### What is Procter & Gamble Hygiene and Health Care's market cap? Procter & Gamble Hygiene and Health Care Ltd's market capitalisation is ₹22,906 Cr at a share price of ₹7,056.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Procter & Gamble Hygiene and Health Care performing? Procter & Gamble Hygiene and Health Care Ltd's share price has been falling for 102 weeks. In its latest quarter, revenue fell 4.9% and profit fell 34.4% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 57 weeks running (as of 3 November 2026). ### Will Procter & Gamble Hygiene and Health Care's share price go up? This page does not forecast Procter & Gamble Hygiene and Health Care Ltd's share price. What it shows instead: the share price is ₹7,056.50, and it has been falling for 102 weeks. Its P/E of 28.9× is higher than 1% of its own last 11 years (as of 3 November 2026). ### Where is Procter & Gamble Hygiene and Health Care in its business cycle? Procter & Gamble Hygiene and Health Care Ltd's Mar 2026 operating margin was 27.0%, against a 13-year range of 20.0% to 29.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 19.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Procter & Gamble Hygiene and Health Care story? The main question: yearly earnings per share moved +34.5% while the share price moved −47.1%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Procter & Gamble Hygiene and Health Care a stock worth studying right now? What the numbers show: Procter & Gamble Hygiene and Health Care Ltd's P/E is near the low end of its own history, higher than only 1% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india
- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india
- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india

This is research, not advice. We’re not SEBI-registered.